Lymph3Cx Assay, Primary Mediastinal Large B-cell Lymphoma and Diffuse Large B-cell Lymphoma, mRNA Gene Expression, NanoString, Tissue
Use
The Lymph3Cx assay is useful for determining a final diagnosis of primary mediastinal large B-cell lymphoma (PMBCL) versus diffuse large B-cell lymphoma (DLBCL). It also provides cell-of-origin information for cases identified as DLBCL. This assay is intended for formalin-fixed paraffin-embedded tissue specimens from patients diagnosed with large B-cell lymphoma.
Special Instructions
A pathology report must accompany the specimen, containing patient name, block number, tissue collection date, and the source of the tissue. Minimum of 60% tumor content is required, with specific guidelines for slide submission based on tumor surface area.
Limitations
This test relies on formalin-fixed paraffin-embedded tissue, which can sometimes suffer from degraded RNA. It is important that tissues have preserved RNA integrity to ensure accuracy. Non-formalin fixed tissue and exhausted tissue blocks are not accepted.
Methodology
Other
Biomarkers
LOINC Codes
- 93785-4
- 93779-7
- 93780-5
- 93781-3
- 93782-1
- 93783-9
Result Turnaround Time
7-12 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit 1 slide stained with hematoxylin and eosin and 7 consecutive, unstained, 5-micron thick sections placed on positively charged slides. Paraffin embedded specimens can be from any anatomic location.
Storage Instructions
Ambient (preferred), Refrigerated
Causes for Rejection
Exhausted tissue block, Tissue with non-formalin fixation